Molecular Mechanisms of HIV-1 Latency from a Chromatin and Epigenetic Perspective

[1]  I. Maridonneau-Parini,et al.  Productive HIV-1 infection of tissue macrophages by fusion with infected CD4+ T cells , 2023, The Journal of cell biology.

[2]  J. Clements,et al.  Monocyte-derived macrophages contain persistent latent HIV reservoirs , 2023, Nature Microbiology.

[3]  J. Ananworanich,et al.  HIV rapidly targets a diverse pool of CD4+ T cells to establish productive and latent infections. , 2023, Immunity.

[4]  O. Gascuel,et al.  In-Depth Characterization of Full-Length Archived Viral Genomes after Nine Years of Posttreatment HIV Control , 2023, Microbiology spectrum.

[5]  R. Siliciano,et al.  Clonally expanded HIV-1 proviruses with 5′-leader defects can give rise to nonsuppressible residual viremia , 2023, The Journal of clinical investigation.

[6]  A. Abate,et al.  HIV silencing and cell survival signatures in infected T cell reservoirs , 2023, Nature.

[7]  E. Rosenberg,et al.  Phenotypic signatures of immune selection in HIV-1 reservoir cells , 2023, Nature.

[8]  E. Rosenberg,et al.  Progressive transformation of the HIV-1 reservoir cell profile over two decades of antiviral therapy , 2022, Cell host & microbe.

[9]  B. Cullen,et al.  Epigenetic silencing by the SMC5/6 complex mediates HIV-1 latency , 2022, Nature Microbiology.

[10]  M. Poirier,et al.  HIV-1 Preintegration Complex Preferentially Integrates the Viral DNA into Nucleosomes Containing Trimethylated Histone 3-Lysine 36 Modification and Flanking Linker DNA , 2022, Journal of virology.

[11]  J. Karn,et al.  Detecting Sources of Immune Activation and Viral Rebound in HIV Infection , 2022, bioRxiv.

[12]  Eugene Kim,et al.  The Smc5/6 complex is a DNA loop-extruding motor , 2022, bioRxiv.

[13]  J. Mullins,et al.  Droplet microfluidic sequencing of HIV proviruses with their integration sites in patients receiving antiretroviral therapy , 2022, Nature Biomedical Engineering.

[14]  L. Montaner,et al.  Single-cell multiomics reveals persistence of HIV-1 in expanded cytotoxic T cell clones. , 2022, Immunity.

[15]  E. Rosenberg,et al.  Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses , 2022, Cell.

[16]  Xianghui Yu,et al.  HIV-1 Vif suppresses antiviral immunity by targeting STING , 2021, Cellular & Molecular Immunology.

[17]  M. Nussenzweig,et al.  Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing , 2021, Proceedings of the National Academy of Sciences.

[18]  E. Verdin,et al.  T cell stimulation remodels the latently HIV-1 infected cell population by differential activation of proviral chromatin , 2021, bioRxiv.

[19]  T. Wrin,et al.  The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy , 2021, Science Translational Medicine.

[20]  J. P. Svensson.  Targeting Epigenetics to Cure HIV-1: Lessons From (and for) Cancer Treatment , 2021, Frontiers in Cellular and Infection Microbiology.

[21]  J. Mullins,et al.  In-depth single-cell analysis of translation-competent HIV-1 reservoirs identifies cellular sources of plasma viremia , 2021, Nature Communications.

[22]  R. Siliciano,et al.  Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption , 2021, Science Translational Medicine.

[23]  S. Goff,et al.  A point mutation in HIV-1 integrase redirects proviral integration into centromeric repeats , 2021, Nature Communications.

[24]  R. Siliciano,et al.  Antigen-driven clonal selection shapes the persistence of HIV-1 infected CD4+ T cells in vivo , 2020, bioRxiv.

[25]  F. Bushman,et al.  Assessment of HIV-1 integration in tissues and subsets across infection stages , 2020, JCI insight.

[26]  J. Siliciano,et al.  Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy. , 2020, The Journal of infectious diseases.

[27]  M. Beck,et al.  Cone-shaped HIV-1 capsids are transported through intact nuclear pores , 2020, Cell.

[28]  R. Siliciano,et al.  A unique viral reservoir landscape in HIV-1 elite controllers , 2020, Nature.

[29]  F. Bushman,et al.  Single-cell transcriptional landscapes reveal HIV-1–driven aberrant host gene transcription as a potential therapeutic target , 2020, Science Translational Medicine.

[30]  Richard D Moore,et al.  Longitudinal study reveals HIV-1-infected CD4+ T cell dynamics during long-term antiretroviral therapy. , 2020, The Journal of clinical investigation.

[31]  Jerome H. Kim,et al.  Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection , 2020, Science Translational Medicine.

[32]  B. Berkhout,et al.  Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART. , 2020, JCI insight.

[33]  R. Siliciano,et al.  Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy. , 2020, JCI insight.

[34]  B. Sherman,et al.  Defective HIV-1 proviruses produce viral proteins , 2020, Proceedings of the National Academy of Sciences.

[35]  C. Kovacs,et al.  BCL-2 antagonism sensitizes cytotoxic t cell-resistant hiv reservoirs to elimination ex vivo. , 2020, The Journal of clinical investigation.

[36]  M. Nussenzweig,et al.  Antigen-responsive CD4+ T cell clones contribute to the HIV-1 latent reservoir , 2020, bioRxiv.

[37]  S. Gianella,et al.  HIV persists throughout deep tissues with repopulation from multiple anatomical sources. , 2020, The Journal of clinical investigation.

[38]  Michele D. Sobolewski,et al.  Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors , 2019, Proceedings of the National Academy of Sciences.

[39]  S. Goff,et al.  Unintegrated HIV-1 DNAs are loaded with core and linker histones and transcriptionally silenced , 2019, Proceedings of the National Academy of Sciences.

[40]  Guillaume J. Filion,et al.  Spatially clustered loci with multiple enhancers are frequent targets of HIV-1 integration , 2019, Nature Communications.

[41]  S. Hughes,et al.  Clones of infected cells arise early in HIV-infected individuals. , 2019, JCI insight.

[42]  J. Wong,et al.  Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals , 2019, AIDS.

[43]  S. Migueles,et al.  Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion , 2019, Nature Communications.

[44]  E. Rosenberg,et al.  Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy , 2019, The Journal of clinical investigation.

[45]  A. Sönnerborg,et al.  Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells , 2019, bioRxiv.

[46]  D. Cooper,et al.  HIV-1 DNA Is Maintained in Antigen-Specific CD4+ T Cell Subsets in Patients on Long-Term Antiretroviral Therapy Regardless of Recurrent Antigen Exposure. , 2019, AIDS research and human retroviruses.

[47]  M. Nussenzweig,et al.  Relationship between intact HIV-1 proviruses in circulating CD4+ T cells and rebound viruses emerging during treatment interruption , 2018, Proceedings of the National Academy of Sciences.

[48]  Eric Verdin,et al.  Anti‐apoptotic Protein BIRC5 Maintains Survival of HIV‐1‐Infected CD4+ T Cells , 2018, Immunity.

[49]  Jeffrey M. Gerold,et al.  TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy , 2018, Science Translational Medicine.

[50]  E. Verdin,et al.  Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4+ T cells , 2018, eLife.

[51]  M. Nussenzweig,et al.  Clonal CD4+ T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation , 2018, Nature Medicine.

[52]  J. Wong,et al.  HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing , 2018, Science Translational Medicine.

[53]  M. Salemi,et al.  The Spleen Is an HIV-1 Sanctuary During Combined Antiretroviral Therapy. , 2017, AIDS research and human retroviruses.

[54]  R. Siliciano,et al.  Transcriptional Reprogramming during Effector‐to‐Memory Transition Renders CD4+ T Cells Permissive for Latent HIV‐1 Infection , 2017, Immunity.

[55]  Youfang Cao,et al.  Nonlatching positive feedback enables robust bimodality by decoupling expression noise from the mean , 2017, bioRxiv.

[56]  R. Siliciano,et al.  Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape. , 2017, Cell host & microbe.

[57]  Andreas Meyerhans,et al.  Position effects influence HIV latency reversal , 2016, Nature Structural &Molecular Biology.

[58]  Jerome H. Kim,et al.  Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand. , 2016, The New England journal of medicine.

[59]  J. Kappes,et al.  Macrophage Infection via Selective Capture of HIV-1-Infected CD4+ T Cells , 2014, Cell host & microbe.

[60]  Brendan B. Larsen,et al.  Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection , 2014, Science.

[61]  T. Meehan,et al.  An atlas of active enhancers across human cell types and tissues , 2014, Nature.

[62]  X. Wang,et al.  Specific reactivation of latent HIV-1 with designer zinc-finger transcription factors targeting the HIV-1 5′-LTR promoter , 2014, Gene Therapy.

[63]  Nan Yan,et al.  Cyclic GMP-AMP Synthase Is an Innate Immune Sensor of HIV and Other Retroviruses , 2013, Science.

[64]  G. Pantaleo,et al.  Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production , 2013, The Journal of experimental medicine.

[65]  T. Mahmoudi,et al.  Repressive LTR Nucleosome Positioning by the BAF Complex Is Required for HIV Latency , 2011, PLoS biology.

[66]  A. Weyrich,et al.  Homeostatic Proliferation Fails to Efficiently Reactivate HIV-1 Latently Infected Central Memory CD4+ T Cells , 2011, PLoS pathogens.

[67]  T. Itoh,et al.  Chromosome length influences replication-induced topological stress , 2011, Nature.

[68]  Suha M. Saleh,et al.  Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton , 2010, Proceedings of the National Academy of Sciences.

[69]  J. Karn,et al.  Establishment of HIV Latency in Primary CD4+ Cells Is due to Epigenetic Transcriptional Silencing and P-TEFb Restriction , 2010, Journal of Virology.

[70]  Geneviève Boucher,et al.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.

[71]  E. Verdin,et al.  Epigenetic Regulation of HIV-1 Latency by Cytosine Methylation , 2009, PLoS pathogens.

[72]  J. Karn,et al.  Epigenetic Silencing of Human Immunodeficiency Virus (HIV) Transcription by Formation of Restrictive Chromatin Structures at the Viral Long Terminal Repeat Drives the Progressive Entry of HIV into Latency , 2008, Journal of Virology.

[73]  Suha M. Saleh,et al.  CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. , 2007, Blood.

[74]  M. L. Simpson,et al.  Transient-mediated fate determination in a transcriptional circuit of HIV , 2007, Nature Genetics.

[75]  F. Bushman,et al.  HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. , 2007, Genome research.

[76]  T. Itoh,et al.  Chromosomal association of the Smc5/6 complex reveals that it functions in differently regulated pathways. , 2006, Molecular cell.

[77]  Paul Shinn,et al.  A role for LEDGF/p75 in targeting HIV DNA integration , 2005, Nature Medicine.

[78]  J. Lifson,et al.  Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. , 2005, The Journal of clinical investigation.

[79]  E. Rosenberg,et al.  Comprehensive Analysis of Human Immunodeficiency Virus Type 1-Specific CD4 Responses Reveals Marked Immunodominance of gag and nef and the Presence of Broadly Recognized Peptides , 2004, Journal of Virology.

[80]  Paul Shinn,et al.  HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots , 2002, Cell.

[81]  Anthony D. Kelleher,et al.  Characterization of CD4+ CTLs Ex Vivo1 , 2002, The Journal of Immunology.

[82]  Z. Grossman,et al.  HIV preferentially infects HIV-specific CD4+ T cells , 2002, Nature.

[83]  F. Marincola,et al.  HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[84]  D. Richman,et al.  Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. , 1999, Science.

[85]  M. Giacca,et al.  HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[86]  M A Nowak,et al.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[87]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[88]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[89]  C. Van Lint,et al.  Transcriptional activation and chromatin remodeling of the HIV‐1 promoter in response to histone acetylation. , 1996, The EMBO journal.

[90]  C. Van Lint,et al.  Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. , 1993, The EMBO journal.

[91]  ofteN oVerlap.  Chronic care of HIV and noncommunicable diseases How to leverage tHe HIv experIence , 2012 .

[92]  J. Gallant,et al.  Antiretroviral therapy. , 2000, The Hopkins HIV report : a bimonthly newsletter for healthcare providers.